Compliance With Live, Oral Ty21a Typhoid Vaccine

Kaplan, Deborah T.

doi:10.1001/jama.1992.03480080044022

Search citation statements

Order By: Relevance

Paper Sections

Select...

Novel Attenuated S Typhi Strains1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1992

2008

Publication Types

Select...

Article5

Book1

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 16 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there have been no compliance issues [54], the need to administer multiple doses to elicit a protective response is viewed as a drawback of Ty21a. Hence, vaccine researchers are attempting to develop novel attenuated S. Typhi strains that may serve as single-dose, oral typhoid vaccines.…”

Section: Novel Attenuated S Typhi Strainsmentioning

confidence: 99%

Vaccines against typhoid fever

Guzmán

Borsutzky

Griot-Wenk³

et al. 2006

Vaccine

143

106

View full text Add to dashboard Cite

Section: Novel Attenuated S Typhi Strainsmentioning

confidence: 99%

Vaccines against typhoid fever

Guzmán

Borsutzky

Griot-Wenk³

et al. 2006

Vaccine

143

106

View full text Add to dashboard Cite

Typhoid Fever in New York City, 1980 Through 1990

Mathieu

Henning²,

Bell³

et al. 1994

Arch Intern Med

View full text Add to dashboard Cite

show abstract

A New Typhoid Vaccine Composed of the Vi Capsular Polysaccharide

Plotkin

Cam²

1995

Arch Intern Med

View full text Add to dashboard Cite

Typhoid is still prevalent in many parts of the world. We reviewed all published and unpublished studies of a newly licensed vaccine composed of the Vi capsular polysaccharide of Salmonella typhi, the causative agent of the disease, which had been licensed previously outside the United States. These included observational studies and double-blind randomized studies done in the United States, Europe, and the developing world in which children and adults unexposed to typhoid or those living in endemic areas were enrolled. A single dose of 25 micrograms of the purified polysaccharide was given by intramuscular injection. The vaccine was well tolerated, inducing only minor reactions in fewer than 10% of subjects. An antibody response occurred in about 90% of subjects and lasted about 3 years. Seroconversion was shown in children as young as 2 years. Protective efficacy was evaluated in two studies conducted in areas in which typhoid is endemic; the efficacy was 55% and 75%, respectively, in adults and in children older than 5 years. The Vi vaccine compares favorably with other typhoid vaccines in regard to safety, patient compliance, immunogenicity, and efficacy. Vi polysaccharide is a well-standardized antigen that is effective in a single parenteral dose, is safer than whole-cell vaccine, and may be used in children 2 years of age or older.

show abstract

Compliance With Live, Oral Ty21a Typhoid Vaccine

Cited by 16 publications

References 7 publications

Vaccines against typhoid fever

Vaccines against typhoid fever

Typhoid Fever in New York City, 1980 Through 1990

A New Typhoid Vaccine Composed of the Vi Capsular Polysaccharide

Contact Info

Product

Resources

About